GD2-SADA

GD2-SADA is a bispecific fusion protein designed for pretargeted radioimmunotherapy (PRIT) of solid tumors expressing the disialoganglioside GD2. The molecule consists of two single-chain variable fragments (scFvs): one targeting the tumor-associated antigen GD2 and another binding to DOTA, a chelator for radiometals such as Lutetium-177. These are linked via a tetramerization sequence derived from p53, allowing the molecule to self-assemble into tetramers with high avidity for tumor targets. Upon administration, unbound tetramers disassemble into monomers that are rapidly cleared by the kidneys, minimizing off-target exposure. In this two-step therapy approach, patients first receive non-radioactive GD2-SADA to localize at tumor sites; after an interval allowing clearance from circulation, a radiolabeled payload (e.g., 177Lu-DOTA) is administered and binds specifically to the prelocalized antibody on tumors. This results in highly focused irradiation of cancer cells while sparing normal tissues. The SADA platform was developed at Memorial Sloan Kettering Cancer Center and is exclusively licensed by Y-mAbs Therapeutics. Clinical development focuses on recurrent or refractory metastatic solid tumors known to express GD2—including high-risk neuroblastoma, small cell lung cancer (SCLC), sarcoma, and melanoma—with ongoing phase 1 trials evaluating safety and tolerability[1][4][5][6][7][8][9].

Other names

anti-GD2 scFv/anti-DOTA scFv fusion proteinGD2-SADA PRITGD-2-SADA PRITGD 2-SADA PRIT